9.30
+0.20
+(2.20%)
At close: February 18 at 7:31:21 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
493,671.00
399,356.00
329,233.00
305,514.00
260,886.00
Cost of Revenue
49,431.00
37,326.00
38,599.00
34,466.00
31,044.00
Gross Profit
444,240.00
362,030.00
290,634.00
271,048.00
229,842.00
Operating Expense
429,839.00
435,524.00
495,060.00
470,968.00
473,696.00
Operating Income
14,401.00
-73,494.00
-204,426.00
-199,920.00
-243,854.00
Net Non Operating Interest Income Expense
-44,805.00
-43,071.00
-34,095.00
-31,962.00
-19,199.00
Other Income Expense
-37,946.00
-33,536.00
-3,518.00
-9,672.00
-11,201.00
Pretax Income
-68,350.00
-150,101.00
-242,039.00
-241,554.00
-274,254.00
Tax Provision
36,338.00
1,483.00
-5,471.00
8,906.00
2,598.00
Net Income Common Stockholders
-104,688.00
-151,584.00
-236,568.00
-250,460.00
-276,852.00
Diluted NI Available to Com Stockholders
-104,688.00
-151,584.00
-236,568.00
-250,460.00
-276,852.00
Basic EPS
-0.34
-0.51
-0.82
-0.92
-1.07
Diluted EPS
-0.34
-0.51
-0.82
-0.92
-1.07
Basic Average Shares
303,023.25
295,164.52
289,057.20
271,421.99
258,867.38
Diluted Average Shares
303,023.25
295,164.52
289,057.20
271,421.99
258,867.38
Total Operating Income as Reported
5,213.00
-77,211.00
-212,120.00
-206,434.00
-246,998.00
Total Expenses
479,270.00
472,850.00
533,659.00
505,434.00
504,740.00
Net Income from Continuing & Discontinued Operation
-104,688.00
-151,584.00
-236,568.00
-250,460.00
-276,852.00
Normalized Income
-86,422.41
-137,640.50
-229,027.88
-245,517.17
-266,536.20
Interest Income
5,662.00
7,078.00
3,024.00
509.00
3,226.00
Interest Expense
50,467.00
50,149.00
37,119.00
32,471.00
22,425.00
Net Interest Income
-44,805.00
-43,071.00
-34,095.00
-31,962.00
-19,199.00
EBIT
-17,883.00
-99,952.00
-204,920.00
-209,083.00
-251,829.00
EBITDA
-9,195.00
-92,079.00
-199,578.00
-202,874.00
-242,983.00
Reconciled Cost of Revenue
49,431.00
37,326.00
38,599.00
34,466.00
31,044.00
Reconciled Depreciation
8,688.00
7,873.00
5,342.00
6,209.00
8,846.00
Net Income from Continuing Operation Net Minority Interest
-104,688.00
-151,584.00
-236,568.00
-250,460.00
-276,852.00
Total Unusual Items Excluding Goodwill
-23,121.00
-17,650.00
-7,694.00
-6,771.00
-10,420.00
Total Unusual Items
-23,121.00
-17,650.00
-7,694.00
-6,771.00
-10,420.00
Normalized EBITDA
13,926.00
-74,429.00
-191,884.00
-196,103.00
-232,563.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-4,855.41
-3,706.50
-153.88
-1,828.17
-104.20
12/31/2020 - 7/8/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
42Z.DU Revolution Medicines Inc
39.20
+2.62%
2GH.MU Merus NV
38.60
-0.52%
4DN.MU Denali Therapeutics Inc.
20.42
0.00%
ISI.DU Ionis Pharmaceuticals Inc
30.21
+2.58%
IONS.MX Ionis Pharmaceuticals, Inc.
619.00
0.00%
ISI.BE Ionis Pharmaceuticals Inc
29.51
+0.34%
2GH.BE Merus NV
40.40
+5.76%
ISI.MU Ionis Pharmaceuticals Inc
29.56
+0.31%
ISI.SG Ionis Pharmaceuticals Inc
30.37
+3.05%
ISI.F Ionis Pharmaceuticals, Inc.
29.56
+0.31%